Rising Government Initiatives Along with Increasing Geriatric Population and Incidence of Chronic Diseases is Driving the Growth of the Hemodialysis Blood Tubing Sets Market

Published: May 2022

The global hemodialysis blood tubing sets market is anticipated to grow at a significant CAGR during the forecast period. The primary factor contributing to the growth of the market is the rising geriatric population across the globe coupled with the rising incidences of various chronic diseases such as cancer, kidney failure, arthritis, and others. Hemodialysis is a treatment used to filter wastes and water from the blood. This treatment supports to control of blood pressure while balancing minerals such as potassium, sodium, and calcium in the blood. People aged above 50 years usually suffer from the problems such as blood pressure and mineral imbalance. According to the United Nations, as of 2019, there were around 705 million people aged above 65 years across the globe, which is further projected to get double by 2050. Furthermore, around 54% of this elderly population is suffering from issues of blood pressure or hypertension. Additionally, these issues turn into chronic disorders if not treated properly and on time, which in turn is expected to lead to the demand for hemodialysis.

Browse the full report description of “Global Hemodialysis Blood Tubing Sets Market Size, Share and Trends Analysis Report by Clinical Application (Detoxification, Mineral Balance, Others), and by End-User (Hospitals and Clinics, Ambulatory Surgical Centers, and Others) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/hemodialysis-blood-tubing-sets-market

Another factor that is expected to propel the growth of the market across the globe during the forecast period is the rising several government initiatives such as approvals for treatment through drugs for different chronic diseases. For instance, in April 2021, the USFDA approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults. Farxiga is majorly prescribed to patients who are already on hemodialysis to reduce risks such as heart failure and others. Thus, the drug can be consumed in combination with hemodialysis.

 Market Coverage

The market number available for – 2021-2028

Base year- 2021

Forecast period- 2022-2028

Segment Covered- 

o By Clinical Application

o By End-User

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

1.1. Competitive Landscape- including Baxter International Inc., Asahi Kasei Medical Co., Ltd., Fresenius SE & Co. KGaA, Nipro Corp., Weigao Holding Co. Ltd., others.

Key questions addressed by the report

What is the market growth rate?

That segment and region dominate the market in the base year?

That segment and region will project the fastest growth in the market?

How does COVID-19 impact the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How players are addressing challenges to sustain growth?

Where is the investment opportunity?

Global Hemodialysis Blood Tubing Sets Market Report by Segment

By Clinical Application

  • Detoxification
  • Mineral Balance
  • Others

By End-User

  • Hospitals and Clinics
  • Ambulatory Surgical Centers 
  • Others

Global Hemodialysis Blood Tubing Sets Market Report Segment by Region

North America

US

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East and Africa


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/hemodialysis-blood-tubing-sets-market